Please login to the form below

Not currently logged in
Email:
Password:

Nabriva Therapeutics adds Will Sargent to team

Join as VP of commercial strategy and investor relations
Will Sargent Nabriva Therapeutics

Nabriva Therapeutics has appointed Will Sargent in the newly created position of vice president of commercial strategy and investor relations.

Sargent has over twenty years of experience in the biopharmaceutical industry, including multiple product and line extension launches. His most recent position was as VP of the orthopaedic business unit at Auxilium Pharmaceuticals.

Nabriva is currently moving rapidly to advance its lead product, lefamulin, into phase III clinical studies which are expected to begin enrolling in 2015 and 2016.

He said: “I am excited to join this talented and dedicated team focused on advancing a novel, targeted antibiotic therapy that can impact patients' lives by addressing an unmet medical need.

“I look forward to applying my experience toward the successful development and implementation of the lefamulin commercial strategy and expansion of corporate communications.”

Dr Colin Broom, CEO of Nabriva, added: “Will's strategic focus, experience and breadth of knowledge will help us plan and execute toward our commercial path goals.”

14th October 2015

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Red Health

Red Health was formed in 2007 to bring something fresh to the healthcare PR world. Our approach was simple –...

Latest intelligence

Precision paediatrics: Treating patients with CAR-T
Dr Stuart Adams specialises in using T-cell therapy to treat paediatric patients at Great Ormond Street Hospital. Here, he explains what it was like to develop and deliver a groundbreaking...
What does it mean to be an agile organisation
We spoke with Philip Atkinson to learn how healthcare and pharmaceutical companies can rapidly respond to changes in the market....
Battling breast cancer with precision medicine (Part 2)
Dr Mark Moasser treated breast cancer survivor Laura Holmes-Haddad (interviewed in part one) with an innovative precision medicine, which at the time was yet to be approved. Here he gives...

Infographics